OWONIKOKO, T. K.; PAPADOPOULOS, K. P.; JOHNSON, M. L.; AL., E. Phase 1 Study of Cemiplimab, a Human Monoclonal Anti-PD-1, in Patients with Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC): Final Efficacy and Safety Data. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 2, p. S78, 2018. DOI: 10.25251/skin.2.supp.78. Disponível em: https://jofskin.org/33014/index.php/skin/article/view/474. Acesso em: 4 jul. 2024.